Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6% - Here's What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s share price dropped 4.6% during mid-day trading on Wednesday . The stock traded as low as $18.06 and last traded at $17.89. Approximately 78,433 shares changed hands during trading, a decline of 72% from the average daily volume of 277,898 shares. The stock had previously closed at $18.75.

Analyst Ratings Changes

DNTH has been the topic of several analyst reports. Guggenheim reaffirmed a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Robert W. Baird dropped their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $53.00.

Dianthus Therapeutics Stock Performance

The company has a market capitalization of $582.74 million, a price-to-earnings ratio of -7.25 and a beta of 1.36. The company's fifty day simple moving average is $18.98 and its two-hundred day simple moving average is $21.19.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.04. The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE boosted its holdings in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after buying an additional 1,510 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at about $33,000. KBC Group NV acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at about $35,000. BNP Paribas Financial Markets acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at about $59,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.